Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should KnowZacks Investment Research • 11/16/23
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023GlobeNewsWire • 11/13/23
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/02/23
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with InhibitorsGlobeNewsWire • 10/31/23
Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake DisordersGlobeNewsWire • 10/25/23
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep CongressGlobeNewsWire • 08/23/23
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023GlobeNewsWire • 08/14/23
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without InhibitorsGlobeNewsWire • 07/10/23
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia BGlobeNewsWire • 05/22/23
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023GlobeNewsWire • 05/12/23
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022GlobeNewsWire • 03/30/23
Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent DirectorPRNewsWire • 03/23/23
Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings?Zacks Investment Research • 03/23/23
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative MedicinesGlobeNewsWire • 03/01/23
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)GlobeNewsWire • 02/06/23
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/02/23
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid TumorsGlobeNewsWire • 01/26/23
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for HemophiliaGlobeNewsWire • 12/10/22
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses to Contact the FirmAccesswire • 11/29/22
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the FirmPRNewsWire • 11/28/22
Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Centessa Pharmaceuticals plc (CNTA) Investors of Class Action Deadline and Encourages Investors to Actively ParticipateBusiness Wire • 11/28/22
Centessa Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 28, 2022 to Discuss Your Rights - CNTANewsfile Corp • 11/28/22